Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Wave Life Sciences Ltd. entered into Implementation Agreement with Wave Life Sciences, Inc. (Wave-Delaware) valued at Exchange all Wave-Singapore ordinary shares for Wave-Delaware common stock on a one-for-one basis; R (effective 2026-04-15).
- Action
- entry
- Agreement
- merger
- Counterparty
- Wave Life Sciences, Inc. (Wave-Delaware)
- Value
- Exchange all Wave-Singapore ordinary shares for Wave-Delaware common stock on a one-for-one basis; R
- Effective
- 2026-04-15
Exact text from the filing
In order to complete the Redomiciliation, the boards of directors of each of Wave-Singapore and Wave Life Sciences, Inc., a Delaware corporation (“ Wave-Delaware ”), approved the entry by Wave-Singapore and Wave-Delaware, respectively, into an Implementation Agreement (the “ Implementation Agreement ”). The Implementation Agreement was executed by Wave-Singapore and Wave-Delaware on April 15, 2026 and provides for a statutory procedure known as a scheme of arrangement (the “ Scheme of Arrangement ”) to be implemented by Wave-Singapore and Wave-Delaware under Singapore law, subject to approval of the shareholders of Wave-Singapore and the High Court of the Republic of Singapore.
View on SEC.gov